CA2385792A1 - Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells - Google Patents
Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells Download PDFInfo
- Publication number
- CA2385792A1 CA2385792A1 CA002385792A CA2385792A CA2385792A1 CA 2385792 A1 CA2385792 A1 CA 2385792A1 CA 002385792 A CA002385792 A CA 002385792A CA 2385792 A CA2385792 A CA 2385792A CA 2385792 A1 CA2385792 A1 CA 2385792A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- lin
- cell
- dcp
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 138
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 title claims abstract description 17
- 238000012512 characterization method Methods 0.000 title description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 238000012258 culturing Methods 0.000 claims abstract description 9
- 239000002243 precursor Substances 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 167
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 23
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 23
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 23
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 230000002187 allostimulatory effect Effects 0.000 claims description 18
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 17
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 17
- 238000005119 centrifugation Methods 0.000 claims description 15
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 12
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 12
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 11
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 11
- 101150013553 CD40 gene Proteins 0.000 claims description 8
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 239000012679 serum free medium Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims 2
- 230000030741 antigen processing and presentation Effects 0.000 claims 1
- 230000035800 maturation Effects 0.000 abstract description 6
- 230000003213 activating effect Effects 0.000 abstract description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 30
- 210000002540 macrophage Anatomy 0.000 description 23
- 210000001616 monocyte Anatomy 0.000 description 23
- 210000003719 b-lymphocyte Anatomy 0.000 description 20
- 239000011324 bead Substances 0.000 description 18
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 16
- 230000000735 allogeneic effect Effects 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 11
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 11
- 238000003556 assay Methods 0.000 description 8
- 238000010348 incorporation Methods 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 230000000139 costimulatory effect Effects 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 5
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011124 ex vivo culture Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 4
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002458 cell surface marker Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- -1 CD86 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003320 cell separation method Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000009118 salvage therapy Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000005135 veiled cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15861899P | 1999-10-08 | 1999-10-08 | |
| US60/158,618 | 1999-10-08 | ||
| PCT/US2000/027651 WO2001027245A2 (en) | 1999-10-08 | 2000-10-06 | Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2385792A1 true CA2385792A1 (en) | 2001-04-19 |
Family
ID=22568957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002385792A Abandoned CA2385792A1 (en) | 1999-10-08 | 2000-10-06 | Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1224262A2 (ja) |
| JP (1) | JP2003511064A (ja) |
| AU (1) | AU7867400A (ja) |
| CA (1) | CA2385792A1 (ja) |
| HK (1) | HK1045329A1 (ja) |
| WO (1) | WO2001027245A2 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113151169A (zh) * | 2021-05-14 | 2021-07-23 | 上海赛笠生物科技有限公司 | 一种基于磁珠阳选策略分离自然杀伤细胞的方法 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7097833B2 (en) | 2002-07-19 | 2006-08-29 | Boston Scientific Scimed, Inc. | Selected cell delivery for heart failure |
| AU2002950778A0 (en) * | 2002-08-15 | 2002-09-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | A method of characterizing dendritic cells |
| AU2003254382B2 (en) * | 2002-08-15 | 2008-11-13 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | A method of characterizing dendritic cells |
| BRPI0411127A (pt) * | 2003-06-10 | 2006-05-23 | Univ Melbourne | composição de matéria para modulação de resposta imuno num sujeito a um antìgeno alvo e respectivos método de modulação, processo de produção de células de apresentação de antìgeno e método de tratamento e/ou profilaxia de doença ou condição associada à presença de antìgeno alvo de interesse |
| ES2379088T3 (es) * | 2004-07-08 | 2012-04-20 | Medinet., Co. Ltd. | Fármaco de células dendríticas que contienen células dendríticas, procedimiento terapéutico usando la célula dendrítica y procedimiento de cultivar células T gamma delta |
| WO2008118369A2 (en) | 2007-03-22 | 2008-10-02 | Dendreon Corporation | Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity |
| KR101349249B1 (ko) * | 2007-08-24 | 2014-01-10 | (주)아모레퍼시픽 | 시험관내 피부 감작성 평가 방법 |
| WO2012123269A1 (en) | 2011-03-11 | 2012-09-20 | Proyecto De Biomedicina Cima, S.L. | Immunogenic compositions and methods for their use |
| EP2505640A1 (en) | 2011-03-29 | 2012-10-03 | Neo Virnatech, S.L. | Vaccine compositions for birnavirus-borne diseases |
| JP6712262B2 (ja) | 2014-09-10 | 2020-06-17 | ミルテニー バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｉｌｔｅｎｙｉ Ｂｉｏｔｅｃ ＧｍｂＨ | 免疫療法に使用するための細胞集団 |
| EP3268012A4 (en) * | 2015-03-12 | 2018-10-31 | Health Research, Inc. | Enrichment of cd16+ monocytes to improve dendritic cell vaccine quality |
| WO2018162450A1 (en) | 2017-03-06 | 2018-09-13 | Fundación Para La Investigación Médica Aplicada | New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells |
| CN109679903A (zh) * | 2019-01-16 | 2019-04-26 | 深圳咖荻生物科技有限公司 | T淋巴细胞的分离纯化方法 |
| CN116103234B (zh) * | 2023-04-13 | 2023-06-23 | 天津纽赛生物技术有限公司 | 一种新型dc样细胞的制备方法及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7659119B2 (en) * | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
| WO1998006823A2 (en) * | 1996-08-14 | 1998-02-19 | Nexell Therapeutics Inc. | Cytokine-free culture of dendritic cells |
| WO1999025812A1 (en) * | 1997-11-14 | 1999-05-27 | Hemosol Inc. | Method for the production and use of dendritic cells |
-
2000
- 2000-10-06 EP EP00968813A patent/EP1224262A2/en not_active Withdrawn
- 2000-10-06 CA CA002385792A patent/CA2385792A1/en not_active Abandoned
- 2000-10-06 JP JP2001530450A patent/JP2003511064A/ja not_active Withdrawn
- 2000-10-06 AU AU78674/00A patent/AU7867400A/en not_active Abandoned
- 2000-10-06 WO PCT/US2000/027651 patent/WO2001027245A2/en not_active Application Discontinuation
-
2002
- 2002-09-14 HK HK02106764.9A patent/HK1045329A1/zh unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113151169A (zh) * | 2021-05-14 | 2021-07-23 | 上海赛笠生物科技有限公司 | 一种基于磁珠阳选策略分离自然杀伤细胞的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003511064A (ja) | 2003-03-25 |
| HK1045329A1 (zh) | 2002-11-22 |
| AU7867400A (en) | 2001-04-23 |
| WO2001027245A3 (en) | 2001-12-13 |
| EP1224262A2 (en) | 2002-07-24 |
| WO2001027245A2 (en) | 2001-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| O'doherty et al. | Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium. | |
| Summers et al. | Phenotypic characterization of five dendritic cell subsets in human tonsils | |
| Kiertscher et al. | Human CD14+ leukocytes acquire the phenotype and function of antigen‐presenting dendritic cells when cultured in GM‐CSF and IL‐4 | |
| Maraskovsky et al. | In vivo generation of human dendritic cell subsets by Flt3 ligand | |
| Pickl et al. | Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes. | |
| Caux et al. | CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+ TNF alpha. | |
| Romani et al. | Generation of mature dendritic cells from human blood An improved method with special regard to clinical applicability | |
| Hunt et al. | Studies of human cord blood dendritic cells: evidence for functional immaturity | |
| Thurner et al. | Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application | |
| Tuyaerts et al. | Generation of large numbers of dendritic cells in a closed system using Cell Factories™ | |
| Duperrier et al. | Distinct subsets of dendritic cells resembling dermal DCs can be generated in vitro from monocytes, in the presence of different serum supplements | |
| CA2133316C (en) | In vitro generation of human dendritic cells and uses thereof | |
| US7198948B2 (en) | Methods and compositions for obtaining mature dendritic cells | |
| Smit et al. | Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells | |
| Almeida et al. | Extensive characterization of the immunophenotype and pattern of cytokine production by distinct subpopulations of normal human peripheral blood MHC II+/lineage− cells | |
| Ryncarz et al. | Expression of CD86 on human marrow CD34+ cells identifies immunocompetent committed precursors of macrophages and dendritic cells | |
| US20080254537A1 (en) | Compositions and Methods for Inducing the Activation of Immature Monocytic Dendritic Cells | |
| Takamizawa et al. | Dendritic cells that process and present nominal antigens to naive T lymphocytes are derived from CD2+ precursors. | |
| Bai et al. | Generation of dendritic cells from human bone marrow mononuclear cells: advantages for clinical application in comparison to peripheral blood monocyte derived cells | |
| Santin et al. | Expression of surface antigens during the differentiation of human dendritic cells vs macrophages from blood monocytes in vitro | |
| CA2385792A1 (en) | Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells | |
| EP0925356A1 (en) | New antigen presenting cells, a process for preparing the same and their use as cellular vaccines | |
| Barratt‐Boyes et al. | Chimpanzee dendritic cells with potent immunostimulatory function can be propagated from peripheral blood | |
| Bella et al. | Are interleukin-16 and thrombopoietin new tools for the in vitro generation of dendritic cells? | |
| Eljaafari et al. | Generation of stable monocyte-derived dendritic cells in the presence of high concentrations of homologous or autologous serum: influence of extra-cellular pH |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |